Modified FOLFIRINOX In Locally Advanced And Metastatic Pancreatic Cancer:a Prospective Study From China

Objective:In order to evaluate the efficiency and safety of modified FOLFIRINOX chemotherapy for Chinese patients with advanced pancreatic cancer.Methods:28 LAPC and 40 MPC patients were treated using modified-FOLFIRINOX(no Fluorouracil bolus,80%Oxaliplatin and 75%Irinotecan)between April 2014 and December 2016.Response rate,safety,conversion rate,surgical outcomes,overall survival(OS)and progression free survival(PFS)were evaluated.Results:The response rate was 26.5%in a total of 68 patients with advanced pancreatic cancer.The most common grade 3/4 adverse events were neutropenia(26.5%)and anemia(14.75%).Surgical treatment was performed in 11 patients with LAPC and the conversion rate was 39.3%.The median OS in the LAPC group was 13m and 10m for MPC.PFS was 13m and 9m in the LAPC and MPC groups,respectively.Conclusions:Modified-FOLFIRINOX resulted in significantly improved tolerance in Chinese advanced pancreatic cancer patients with similar efficacy and an acceptable toxicity rate.These data might provide guidance for FOLFIRINOX use in Chinese patients with advanced pancreatic cancer.